HOME >> BIOLOGY >> NEWS
Other highlights in the September 7 JNCI

ding ER activity in PR-negative breast cancer. "These data could have a profound translational clinical impact on directing therapeutic interventions for patients who have ER-positive tumors but who display a steroid hormoneresistant or independent phenotype," they write.

Contact:

  • Article: Kimberlee Barbour, Baylor College of Medicine, 713-798-4712, kbarbour@bcm.edu
  • Editorial: Kim Irwin, University of California Los Angeles, 310-206-2805, kirwin@mednet.ucla.edu

    Hirschsprung Disease Gene May Also Be Involved in Some Melanomas

    A new study has found that mutations in a gene involved in Hirschsprung disease--a rare disease of the colon that usually occurs in children--may also predispose carriers to malignant melanoma.

    Because the endothelin signaling pathway plays an important role in the differentiation and migration of melanocytes, the cells from which melanomas arise, Nadem Soufir, M.D., Ph.D., of the Hopital Bichat-Claude Bernard in Paris, and colleagues investigated whether mutations in the gene endothelin receptor B (EDNRB), which is involved in Hirschsprung disease, could also predispose individuals to malignant melanoma. They sequenced the gene in 137 patients with malignant melanoma and 130 matched control subjects.

    EDNRB mutations were identified in four control subjects and in 15 patients, 14 of whom carried mutations reported in Hirschsprung disease and/or resulted in loss of gene function. The authors found a direct association between melanoma risk and the presence of EDNRB mutations. They conclude that their data strongly suggest that EDNRB is involved in the predisposition of two different multigenic disorders, Hirschsprung disease and melanoma.

    Contact: Nadem Soufir, Hopital Bichat-Claude Bernard, nadem.soufir@bch.ap-hop-paris.fr

    Treatment
    '"/>



  • Contact: Sarah L. Zielinski
    jncimedia@oxfordjournals.org
    301-841-1287
    Journal of the National Cancer Institute
    6-Sep-2005


    Page: 1 2 3 4

    Related biology news :

    1. Other highlights in the Aug. 7 JNCI
    2. Other highlights in the July 24 JNCI
    3. Other highlights from the July 10 JNCI
    4. Other highlights in JNCI, June 26
    5. Other highlights in JNCI, June 12
    6. Other highlights from the June 6 JNCI
    7. Other highlights in the May 16 JNCI
    8. Other highlights from the April 18 Journal of the National Cancer Institute
    9. Other highlights from the March 21 JNCI
    10. Other highlights in the March 7 JNCI
    11. Other highlights in the Feb. 21 JNCI

    Post Your Comments:
    *Name:
    *Comment:
    *Email:


    (Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
    (Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
    (Date:3/28/2017)... , March 28, 2017 ... Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video ... and Region - Global Forecast to 2022", published by ... in 2016 and is projected to reach USD 75.64 ... 2017 and 2022. The base year considered for the ...
    Breaking Biology News(10 mins):
    (Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for ... June 2018 in San Francisco, CA. The Summit brings together current and former FDA ... board directors and government officials from around the world to address key issues in ...
    (Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
    (Date:10/11/2017)... ... October 11, 2017 , ... Singh ... orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of ... SBT-100 is able to cross the cell membrane and bind intracellular STAT3 and ...
    (Date:10/10/2017)... ... 10, 2017 , ... For the second time in three ... Mentoring Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October ... US2020’s mission is to change the trajectory of STEM education in America by ...
    Breaking Biology Technology:
    Cached News: